Showing 5551-5560 of 6808 results for "".
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest ap
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns
- Dermavant Completes Enrollment for Long-Term Safety Study of Tapinarof in Adult Psoriasishttps://practicaldermatology.com/news/dermavant-completes-enrollment-for-long-term-safety-study-of-tapinarof-in-adult-psoriasis/2460416/Patient enrollment in Dermavant’s long-term safety study of tapinarof is now complete, the company says. Tapinarof is a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) being investigated for use in adult patients diagnosed with plaq
- New from Obagi: Two Sunscreens and a Hydrating Serumhttps://practicaldermatology.com/news/new-from-obagi-two-sunscreens-and-a-hydrating-serum/2460415/Obagi is launching two new Physical Defense Sunscreens and Daily Hydro-Drops. The new SUZANOBAGIMD Physical Defense Sunscreens, available in broad-spectrum SPF 40 and tinted SPF 50, defend against five light sources, including high energy visible light, or blue light, visible light
- Pfizer’s JAK Inhibitor Improves Moderate-to-Severe AD Symptomshttps://practicaldermatology.com/news/pfizers-jak-inhibitor-improves-mild-to-moderate-ad-symptoms/2460413/Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an investigational oral once-daily JAK1 inhibitor being studied in
- FDA Approves Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe ADhttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-ad/2460404/The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Dupixent comes in two doses, prescribed based on weight (300 mg every four weeks for children ≥15 to <30 kg and 200 mg eve
- Industry Responds to COVID-19: Dial Donates Products to FEMA, Encourages Americans to Participate in #IWashMyHandsFor Social Campaignhttps://practicaldermatology.com/news/industry-responds-dial-donates-products-to-fema-encourages-americans-to-participate-in-iwashmyhandsfor-social-campaign/2460398/Dial will donate more than 600,000 units of liquid hand soap, bar soap and body wash products to FEMA, supporting their mission to help people during disasters. In March 2020 Henkel announced a comprehensive
- To Test or Not to Test? Practices Weigh COVID-19 Testing of Patients and Staff as Part of Reopening Planshttps://practicaldermatology.com/news/to-test-or-not-to-test-practices-weigh-covid-19-testing-of-patients-and-staff-as-part-of-reopening-plans/2460395/COVID-19 antibody testing can play an important role in identifying people who have recovered from the SARS-CoV-2 virus and who have high levels of antibodies in their blood that could potentially help other critically ill COVID-19 patients. The presence of antibodies may also suggest immuni
- Done Deal: AbbVie Completes Acquisition of Allerganhttps://practicaldermatology.com/news/done-deal-abbvie-completes-acquisition-of-allergan/2460389/AbbVie completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. In connection with the closing of the transaction, the AbbVie Board of Directors has elec
- SciBase Receives FDA Approval for Nevisense 3.0https://practicaldermatology.com/news/scibase-receives-fda-approval-for-nevisense-30/2460388/The FDA has approved SciBase AB's Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in